Does Anthem (Elevance Health) Cover Wegovy?

Anthem's Current Coverage Policy for Wegovy

Anthem (Elevance Health) classifies Wegovy as a covered benefit under most commercial PPO and HMO formularies, subject to prior authorization (PA) and mandatory step therapy. This policy applies to the FDA-approved indication of chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [1].

Coverage is not automatic. Anthem requires the prescribing clinician to submit clinical documentation proving the patient meets specific BMI and comorbidity thresholds before a single pen ships from the pharmacy. Self-funded employer plans administered by Anthem may opt out of anti-obesity medication coverage entirely, so the first step is always confirming your specific plan's drug benefit. You can do this by calling the number on the back of your Anthem card or checking the formulary lookup tool on anthem.com.

The Endocrine Society's 2024 guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥ 30 who have not achieved target weight loss through lifestyle intervention alone [2]. Anthem's PA criteria broadly align with this recommendation, though the insurer adds a step-therapy layer that the guidelines do not require.

Prior Authorization Criteria: What Anthem Requires

Anthem's PA form for Wegovy asks for five categories of clinical evidence. Understanding each one can prevent a rejection on the first submission.

1. BMI documentation. The prescriber must record a BMI ≥ 30, or ≥ 27 with at least one comorbidity. The NIH clinical guidelines on obesity define these cutoffs and list qualifying comorbidities including type 2 diabetes, obstructive sleep apnea, and cardiovascular disease [3]. Anthem accepts BMI calculated from a clinical visit within the past 90 days.

2. Lifestyle intervention history. Documentation of participation in a structured diet and exercise program for at least 3 months is expected. The USPSTF recommendation on behavioral weight-loss interventions supports this requirement, grading intensive behavioral counseling as a B recommendation [4].

3. Step therapy completion. Anthem requires documented trial and failure (or contraindication) of at least one lower-cost anti-obesity medication. Acceptable agents typically include orlistat, phentermine/topiramate (Qsymia), or naltrexone/bupropion (Contrave). A "failure" means the patient did not achieve ≥ 5% total body weight loss after at least 3 months at adequate dose, consistent with the AGA clinical practice guideline threshold for pharmacotherapy response [5].

4. Prescriber specialty. Some Anthem plans require the prescribing clinician to be an endocrinologist, obesity medicine specialist, or primary care physician with documented obesity management training. This is not universal across all Anthem products.

5. No concurrent GLP-1 use. Anthem will deny Wegovy if the patient is concurrently prescribed another GLP-1 receptor agonist such as Ozempic (semaglutide 1 mg for diabetes) or Mounjaro (tirzepatide). The FDA label for Wegovy explicitly states it should not be used with other semaglutide-containing products [1].

Standard PA review takes 5 to 10 business days. Urgent requests (patient with BMI ≥ 40 and immediate surgical risk, for example) may be processed in 24 to 72 hours.

Formulary Tier and Out-of-Pocket Costs

On most Anthem commercial plans, Wegovy sits on the specialty tier. That is Tier 4 or Tier 5, depending on the specific plan design. Specialty-tier drugs carry the highest cost-sharing, often structured as coinsurance (25% to 33% of the allowed amount) rather than a flat copay.

At Wegovy's list price of $1,349 per month, a 30% coinsurance translates to roughly $405 out of pocket before reaching any annual out-of-pocket maximum. Some Anthem PPO plans cap specialty copays at $150 to $250 per fill, which reduces the monthly burden substantially. The KFF employer health benefits survey found that the median specialty-tier copay across all commercial plans was $100 to $150 in 2024 [6].

Novo Nordisk offers a manufacturer savings card that reduces copays to as low as $0 for commercially insured patients. Eligibility requires active commercial insurance coverage (not Medicare, Medicaid, or Tricare). Patients with Anthem commercial plans can typically combine the savings card with their insurance benefit, covering the gap between the plan's copay and $0. The savings card has an annual cap, currently $500 per month or $6,000 per year in benefit.

For patients whose Anthem plan excludes anti-obesity medications or whose self-funded employer has carved out the benefit, the full cash price of $1,349 per month applies. In that scenario, the Novo Nordisk patient assistance program (PAP) may provide Wegovy at no cost for household incomes below 400% of the federal poverty level, per Novo Nordisk's patient access page.

The Step Therapy Requirement Explained

Step therapy is Anthem's most common barrier to Wegovy approval. The insurer's rationale: try less expensive medications first, then escalate.

Generic orlistat (Xenical) costs approximately $50 to $80 per month and works by blocking dietary fat absorption. The XENDOS trial showed orlistat produced 5.8 kg mean weight loss over 4 years versus 3.0 kg with placebo, a modest effect [7]. Phentermine/topiramate ER (Qsymia) produced 9.8% mean weight loss at the top dose in the CONQUER trial (N=2,487), making it the most potent oral option [8]. Naltrexone/bupropion (Contrave) delivered approximately 5% to 6% mean body weight reduction in the COR-I trial [9].

Compare these to semaglutide 2.4 mg. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [10]. That is a categorically different magnitude of effect. The STEP-3 trial combined semaglutide 2.4 mg with intensive behavioral therapy and reported 16.0% mean body weight reduction at 68 weeks [11].

To satisfy step therapy, document the prior medication trial thoroughly. Include start date, dose titration, duration (minimum 90 days), weight change in kilograms, and reason for discontinuation (inadequate response, intolerable side effects, or contraindication). Vague notes like "patient tried orlistat" will be rejected.

Clinicians can request a step-therapy exception if a clinical contraindication exists to all step-therapy agents. For instance, phentermine is contraindicated in uncontrolled hypertension, and bupropion-containing products are contraindicated in seizure disorders. Document the contraindication explicitly in the exception request.

How to Appeal an Anthem Denial for Wegovy

A denied PA is not the end of the road. Anthem operates a two-level internal appeal process, followed by access to an external independent review organization (IRO) mandated by state insurance law.

Level 1: Internal Appeal. File within 180 days of the denial letter. Include the original PA documentation plus any new clinical evidence. A peer-to-peer review, where your prescribing physician speaks directly with Anthem's medical director, is available at this stage and can be requested by calling the PA department. The AMA guide to prior authorization reform reports that 42% of PA denials are overturned when physicians pursue peer-to-peer conversations [12]. Ask your doctor to reference the patient's specific clinical trajectory, failed step therapy agents, and current cardiovascular risk profile during the call.

Level 2: Second Internal Appeal. If Level 1 fails, Anthem conducts a second review by a physician who was not involved in the first decision. Submit additional supporting literature. The STEP-5 trial showing sustained weight loss over 104 weeks is useful for appeals questioning long-term efficacy [13]. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity [14]. This trial led to the FDA-expanded indication for cardiovascular risk reduction in March 2024 [15].

External IRO Review. After exhausting both internal appeals, you can request external review through your state's insurance department. The IRO is an independent panel that reviews the clinical case without Anthem's involvement. IRO decisions are binding on the insurer in most states. The timeline is typically 30 to 45 days for standard cases, or 72 hours for expedited review when the patient faces imminent health risk.

Anthem Medicare Advantage and Medicaid Plans

Coverage differs substantially for Anthem Medicare Advantage and Medicaid managed-care members. Medicare Part D has historically excluded anti-obesity medications from formulary coverage under the Social Security Act. However, the Treat and Reduce Obesity Act has been reintroduced in Congress and, if passed, would require Medicare Part D coverage of FDA-approved anti-obesity drugs [16].

Some Anthem Medicare Advantage plans have begun offering supplemental weight-management benefits that partially cover GLP-1 medications through a separate benefit rider. This is plan-specific and geography-dependent. Members should call Anthem directly or review their Evidence of Coverage (EOC) document.

For Anthem Medicaid managed-care enrollees, coverage depends on the state. As of 2026, 14 state Medicaid programs cover at least one GLP-1 for obesity, according to analysis by the Obesity Action Coalition. Anthem administers Medicaid plans in states including Indiana, Ohio, Virginia, and Georgia. Each state's preferred drug list dictates whether Wegovy is accessible.

Clinical Outcomes That Support Your Case

Beyond the STEP trials, several data points strengthen a PA submission or appeal.

The STEP-2 trial specifically enrolled patients with type 2 diabetes (N=1,210) and showed 9.6% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 3.4% with placebo, along with significant HbA1c reductions [17]. For Anthem members with concurrent diabetes, this trial directly supports dual benefit.

A 2023 real-world analysis published in JAMA Network Open found that patients initiating semaglutide in clinical practice lost a mean of 5.9% body weight at 3 months and 10.9% at 12 months, confirming that trial results translate to routine care settings [18].

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends GLP-1 receptor agonists as preferred pharmacotherapy for patients with BMI ≥ 30 who have not reached target weight loss with lifestyle modification [19]. Citing this guideline by name in PA paperwork signals that the request aligns with specialty society consensus.

Dr. Robert Kushner, professor of medicine at Northwestern University and co-author of the STEP program, has stated: "The magnitude of weight loss with semaglutide 2.4 mg exceeds anything we have seen with prior anti-obesity medications. It represents a new standard of care for patients with obesity who need pharmacotherapy."

Timeline: From Prescription to First Injection

A realistic timeline for an Anthem-covered Wegovy prescription follows this pattern. Week 1: prescriber submits PA with full clinical documentation. Week 1 to 2: Anthem reviews and either approves, requests additional information, or denies. Week 2 to 3: if approved, specialty pharmacy processes the prescription and ships the medication (Wegovy is dispensed through specialty pharmacy channels on most Anthem plans). Week 3 to 4: patient receives medication and begins the dose-escalation schedule at 0.25 mg weekly for the first 4 weeks, per the FDA-approved titration schedule [1].

If denied, add 2 to 4 weeks for the Level 1 appeal and potential peer-to-peer review. The full cycle from initial denial to IRO decision can take 8 to 12 weeks.

To shorten the timeline, submit complete documentation on the first PA attempt. Missing lab values, vague step-therapy records, or absent BMI calculations are the most common reasons Anthem requests additional information, which resets the review clock.

Strategies to Reduce Your Out-of-Pocket Cost

Several approaches can lower monthly spending on Wegovy under Anthem plans.

Manufacturer savings card. As noted above, commercially insured patients can reduce copays to $0 per fill. Enroll through the Wegovy website or have your prescriber's office submit enrollment during the PA process.

Preferred specialty pharmacy. Anthem designates preferred specialty pharmacies (often Express Scripts or CarelonRx) that carry lower copays than non-preferred pharmacies. Confirm your plan's preferred specialty pharmacy before the prescription is submitted.

Accumulator adjuster programs. Some Anthem plans use copay accumulator programs that prevent manufacturer savings card payments from counting toward your annual out-of-pocket maximum. If your plan has an accumulator, the savings card still reduces your monthly cost, but it will not help you reach your deductible or OOP max faster. Check your Summary of Benefits for language about "third-party payment" or "accumulator adjustment."

Annual OOP maximum. Under the ACA out-of-pocket limits, the 2026 individual OOP maximum is $9,450 for in-network services [20]. Once reached, Anthem pays 100% of covered drugs, including Wegovy, for the remainder of the plan year.

Patients who start Wegovy in January and have high medication costs from other conditions may reach their OOP maximum mid-year, at which point Wegovy becomes free for the remaining months.